Spyre Therapeutics (SYRE) Payables: 2015-2025
Historic Payables for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $7.5 million.
- Spyre Therapeutics' Payables rose 44.38% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year decrease of 61.68%. This contributed to the annual value of $666,000 for FY2024, which is 95.98% down from last year.
- Latest data reveals that Spyre Therapeutics reported Payables of $7.5 million as of Q3 2025, which was up 100.89% from $3.7 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Payables ranged from a high of $20.8 million in Q2 2023 and a low of $666,000 during Q4 2024.
- Its 3-year average for Payables is $9.0 million, with a median of $5.2 million in 2024.
- In the last 5 years, Spyre Therapeutics' Payables skyrocketed by 2,349.63% in 2023 and then crashed by 95.98% in 2024.
- Over the past 5 years, Spyre Therapeutics' Payables (Quarterly) stood at $3.3 million in 2021, then slumped by 79.60% to $677,000 in 2022, then skyrocketed by 2,349.63% to $16.6 million in 2023, then tumbled by 95.98% to $666,000 in 2024, then soared by 44.38% to $7.5 million in 2025.
- Its Payables was $7.5 million in Q3 2025, compared to $3.7 million in Q2 2025 and $3.7 million in Q1 2025.